Next Article in Journal
Low Galectin-3 Expression Level in Primary Tumors Is Associated with Metastasis in T1 Lung Adenocarcinoma
Next Article in Special Issue
Mean Platelet Volume as a Marker of Vasculogenic Erectile Dysfunction and Future Cardiovascular Risk
Previous Article in Journal
The Efficacy of Rotary, Reciprocating, and Combined Non-Surgical Endodontic Retreatment Techniques in Removing a Carrier-Based Root Canal Filling Material from Straight Root Canal Systems: A Micro-Computed Tomography Analysis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 9
Issue 6
10.3390/jcm9061991
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Erectile Dysfunction after Kidney Transplantation

by
Anna Perri
1,
Giulia Izzo
2,
Danilo Lofaro
1,
Sandro La Vignera
3,
Antonio Brunetti
4,
Aldo Eugenio Calogero
3 and
Antonio Aversa
2,*
1
Kidney and Transplantation Research Center, Department of Nephrology, Dialysis and Transplantation, Annunziata Hospital, 87100 Cosenza, Italy
2
Department of Experimental and Clinical Medicine, Magna Graecia University Catanzaro, 88100 Catanzaro, Italy
3
Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
4
Department of Health Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, Italy
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(6), 1991; https://doi.org/10.3390/jcm9061991
Submission received: 21 May 2020 / Revised: 12 June 2020 / Accepted: 22 June 2020 / Published: 25 June 2020
(This article belongs to the Special Issue Erectile Dysfunction in Men with Chronic Diseases: From Pathophysiology to Clinical Management)
Versions Notes

Abstract

:
Patients with kidney transplantation often have a worse quality of life than the general population. One of the reasons for this, in male patients, is the high prevalence of erectile dysfunction. This is mainly due to the presence of comorbidities, surgery for kidney transplantation, adverse drug effects, psychological changes related to chronic disease, as well as hyperprolactinemia and hypogonadism. Whenever these endocrine dysfunctions occur after kidney transplantation, they must be corrected with appropriate treatment, i.e., testosterone replacement therapy. Administration of the phosphodiesterase-5 inhibitor (PDE5i) sildenafil at the recommended posology does not significantly alter the pharmacokinetics of the calcineurin inhibitors cyclosporin A or tacrolimus and does not impair kidney allograft function. Tacrolimus increases the peak concentration and prolongs the half-life of PDE5i in kidney transplant patients and, therefore, daily administration cannot be recommended due to the significant drop in blood pressure. Intracavernous injection or topical application of alprostadil can be a second-line option for the treatment of erectile dysfunction after kidney transplantation, which does not alter cyclosporine concentrations and does not deteriorate kidney function. Finally, penile prostheses can be successfully implanted following pelvic organ transplantation after eliminating the risk of infection associated with surgery.

1. Introduction

Impaired sexual function is very common in end-stage renal disease (ESRD) patients, with a prevalence of 60–90% in both genders [1,2,3]. Although improvement of sexual dysfunction has been reported after kidney transplantation [4,5,6], some studies have shown that this condition can persist even after successful transplantation [7,8].
In a systematic review and meta-analysis of 50 studies, the rate of erectile dysfunction (ED) in patients with chronic kidney disease (CKD) was shown to be 75%, whereas it decreased to 59% in kidney transplantation recipients (KTRs). This suggests that restoration of the glomerular filtration rate (GFR) after transplantation may improve erectile function, although the reduction in ED severity and prevalence might depend on the predominant etiological mechanism [2]. The high rate of ED in KTR patients may be ascribed to various factors, such as long-term uremia, persistent sex hormone abnormalities (decreased testosterone and increased LH, FSH, and prolactin levels), and vascular modifications of penis arteries caused by iliorenal artery anastomosis, the introduction of immunosuppressive drugs, and the high rate of anxiety and depression [9,10]. Furthermore, many KTRs have multiple risk factors for ED, including diabetes and hypertension, while transplantation does not have any effect on these underlying risk factors [11].
The availability of published data that can be used to compare pre- and post-transplantation erectile function, as well as to evaluate the response to treatments, is very limited. Moreover, the main limitations of these studies are their reliance on a small number of patients investigated and the suboptimal or lack of uniform assessment of the outcome measures. In the present article, we perform a Medline search in the attempt to review the most important clinical and experimental lines of evidence on the main factors influencing the onset of ED after renal transplantation or their persistence/improvement after dialysis interruption. Furthermore, because of the paucity of the studies, we aim to highlight the best practice in the treatment of ED in KTRs, underlying that sexual dysfunction is an underestimated topic by nephrologists in both men and women with CKD, also after kidney transplantation.

2. Factors Influencing ED after Kidney Transplantation

In KTRs, ED has a multifactorial etiology since either organic, psychological, or mixed abnormalities are involved [12]. Predisposing factors usually include conditions/comorbidities related to CKD [12], which may not always be corrected by transplantation [13,14]. The beneficial effect of kidney transplantation is still controversial [13,14]. While some authors have reported an improvement of ED in KTRs [12,15], others have pointed out a persistent or de-novo onset of ED [4,12,16]. Indeed, the systemic organic damage in patients with CKD, comorbidities, and hemodialysis shows a progressive and irreversible course, which is frequently unresponsive to transplantation and may negatively impact KTRs’ sexual function [16,17].
Dysfunctions of the hypothalamic–pituitary–gonadal (HPG) axis play a crucial role in the pathogenesis of ED (Table 1). In particular, testosterone deficiency may negatively impact on penile structure, function, and hemodynamics, leading to ED [12,17]. Moreover, hormonal abnormalities (Table 1) such as hypogonadism (primary or secondary), hyperprolactinemia, and secondary hyperparathyroidism may improve or persist after transplantation [12]. Besides hormonal dysfunctions, many other preexisting conditions (Table 1) such as diabetes mellitus and metabolic risk factors, autonomic nervous system disturbances, peripheral neuropathy, cardiovascular, and endothelial dysfunctions, or a combination of these disorders, in addition to anemia, secondary hyperparathyroidism, drugs, psychological factors, age, voluptuous habits, and education, may differently impact ED in KTRs [12,18]. In particular, metabolic syndrome and diabetes mellitus are often associated with lower testosterone levels, and may also cause ED through endothelial damage and a multifactorial prothrombotic state, leading to arteriopathy and neuropathy [12,19]. In patients with CKD, several molecular and ultrastructural abnormalities may lead to damage of cavernous tissue and distal penile arteries [16]. Indeed, persistent penile anatomical abnormalities, usually occurring in uremic patients, include changes in smooth muscle cells, which are characterized by the reduction of dense bodies in the cytoplasm, thickening of the basement membrane, interstitial fibrosis (with a reduction in cell-to-cell contacts), thickening and lamination of basement membranes of endothelial cells, and increased accumulation of collagen between nerve fibers [20]. Besides the metabolic disturbances, anemia (Table 1) is also involved in penile morphological and functional damage [20].
Moreover, the duration of hemodialysis before transplantation, a lower diastolic blood pressure, and peripheral arteriopathy can also influence ED in KTRs [4]. After transplantation, age, comorbidities, drugs, vascular conditions, transplant surgical procedures, iterative transplantation, voluptuous habits, interpersonal problems, altered body image perception, and psychological factors (e.g., self-esteem, stress, and depression) may impact on ED (Table 1) [12,16,17]. In particular, age is an important risk factor for both pre- and post-transplantation ED [12], and it is directly correlated with the severity of ED [13]. Tian and colleagues reported a prevalence of ED of 60% in patients <30 years old, 66% in those of 31–40 years; 75% in those of 41–50 years; 87% in those of 51–60 years, and 92% in >60 years [20]. In contrast, a prospective, interventional, nonrandomized study showed that erectile function worsened in KTRs <45 years, whereas it did not change in KTRs >45 years old [16].
Education displays an inverse correlation with ED, which may be explained by less attention to healthcare, quality of life, and sexuality in people with low education [20]. The role of voluptuous habits, such as smoking/drinking, is still unclear. Smoking notoriously shows detrimental effects on erectile function [16]; however, some studies reported no association with ED in KTRs [4,16].
The duration of the hemodialytic treatment, which patients have undergone before kidney transplantation, also affects erectile function in KTRs [14,16,20]. Improvement of ED has been reported in KTRs who underwent dialysis for 6 months, whereas those who were dialyzed for 6–24 months showed no ED improvement. This may probably be due to the effect of early transplantation in preventing/reversing penile morphological/functional and hemodynamic abnormalities, as well as hormonal dysfunctions [14]. Data on the association between ED and professional factors or graft durations are unclear, though some authors have reported no association with erectile function [20]. Although comorbidities such as diabetes mellitus and/or peripheral neuropathy, dyslipidemia, and hypertension are independent risk factors, KTRs sometimes pay particular attention to control these pathologies to delay chronic allograft nephropathy. Therefore, the impact of these factors on ED may be variable [20].
Drugs such as immunosuppressant and antihypertensive agents are involved in the onset of ED in KTRs. In particular, calcineurin inhibitors (CNIs), i.e., cyclosporine, tacrolimus, mTOR inhibitors, as well as corticosteroids, may impact on the endothelial function [13,14,16,17] and/or the testicular function/structure [13].
Surgical procedures during transplantation, such as the interruption of iliac artery distal ends, may sometimes cause insufficiency of penile blood flow, leading to ED [17,20]. The type of arterial anastomosis differently influences the prevalence of ED in KTRs because of the impact on cavernosal artery hemodynamics [21]. Evidence reports an increased ED in KTRs revascularized through end-to-end anastomosis to the internal iliac artery compared to end-to-side anastomosis to the external iliac artery, suggesting a negative role of the unilateral ligation of the internal iliac artery in erectile function following kidney transplantation [21]. Indeed, when the kidney graft is anastomosed end-to-end to the internal iliac artery, the blood inflow from the internal pudendal artery is diverted [21]. However, the prevalence of ED is still high even in KTRs revascularized through anastomosis at the external iliac artery [21], which shows a slight reduction in penile arterial inflow [21]. Moreover, penile hypoafflux and ED may also be worsened or caused by iterative transplantation when the internal iliac artery is more likely used for end-to-side anastomosis [20].
Finally, psychological factors such as self-esteem, altered body image perception, worrying, anxiety, and depression (which are related to kidney disease and transplantation) usually affect erectile functioning [20,22]. Indeed, many symptoms in KTRs may derive from somatic and psychosocial comorbidities persisting after the transplantation procedure [13].

3. Impact of Immunosuppressant Drugs on ED

The goals of immunosuppressive therapy in KTRs are to prevent graft rejection and complications and to reduce morbidity. KTRs are maintained on an immunosuppression regimen that includes one to three drugs. The major immunosuppressive agents used in these patients are CNIs, cyclosporin A (CsA) and tacrolimus, mammalian target of rapamycin—mTOR—inhibitors (sirolimus and everolimus), antimetabolites (azathioprine, mycophenolate-mofetil), and glucocorticoids (prednisone) [23].
Nowadays, CNIs constitute the cornerstone of the immunosuppression regimen following kidney transplantation [24]. However, these drugs are known to be nephrotoxic and can cause acute and/or chronic toxicity on the graft [25,26], concomitantly contributing to the new onset of diabetes [27] and hypertension [28]. Growing literature has shown that CNI minimization or conversion to alternative non-nephrotoxic maintenance immunosuppressants, using mTOR inhibitors or the costimulation blocker belatacept, may improve long-term allograft function and survival, reducing the correlated complications [29,30]. The evidence published on the correlation between CNI-based immunosuppressive regimens and ED in KTRs is controversial [4,31,32,33,34]. The study of El-Assmy and colleagues showed that ED was more prevalent among patients receiving CsA, highlighting that CsA may negatively impact penile hemodynamics through different mechanisms, leading to ED [35]. Data on this topic reported that treatment with CsA increases median blood pressure, concomitantly suppressing nitric oxide (NO)-mediated smooth muscle relaxation, essential for erection [36]. Moreover, in endothelial cells, therapeutic doses of CsA, by reducing caveolae cholesterol content, promoted the translocation of eNOS from caveolae, leading to a decreased generation of NO [37,38]. Interestingly, CsA-induced NO modulation, by upregulating TGF-β1 expression, increases matrix deposition and decreases matrix degradation [39]. This effect, concomitantly with a reduction of collagen degradation promoted by CsA exposure in both epithelial and fibroblast cells [40], may induce fibrosis of the corpora cavernosa.
Although vascular pathology represents the key mechanism underlying ED, it has been reported that testosterone deficiency may affect erectile function [41]. Several experimental models have investigated the effects of CsA on spermatogenesis and endocrine function, demonstrating that CsA inhibits the growth and the steroidogenic capacity of rat Leydig cells [42,43], and this effect occurs in a dose-dependent manner [44]. This suggests that CsA-induced hypogonadism may represent a mechanism involved in ED.
Recent advances have elucidated the crucial role of mTOR in the male reproductive potential [45]. However, several studies have shown that mTOR-inhibitors, mainly sirolimus, negatively impact male gonads of KTRs after a few years of treatment. Nevertheless, the underlying molecular mechanisms remain not completely understood [45]. Certainly, male infertility represents the most striking side effect, and sirolimus causes a decrease in sperm count, motility, and viability [46,47,48]. Furthermore, in-vivo studies have revealed that doses of rapamycin equivalent to therapeutic levels affect testicular development and HPG axis function and induce marked histological changes of testicular structures. The last ones include dystrophy of seminiferous tubules, leading to the impairment of spermatogenesis [49,50,51]. Some studies have reported that sirolimus is associated with a decrease in serum total testosterone levels, concomitantly with a rise of LH and FSH, although it is unclear whether sirolimus-related hypogonadism impairs the erectile function [13,52,53,54,55].
No data are available to assess whether everolimus is more or less gonadotoxic than sirolimus. Interestingly, it has been reported that the side effects on spermatogenesis, as well as on sex hormones, may be reversible by switching from the administration of mTOR-inhibitors to other immunosuppressants [49]. Immunosuppressive therapeutic strategy in KTRs frequently includes corticosteroids that significantly reduce acute rejection, but cause several long-term adverse effects, even at low doses. Therefore, some studies have suggested quitting glucocorticoids after kidney transplantation, even if the optimal time point has not yet been established [56]. Glucocorticoids decrease testosterone synthesis directly via gonadal steroid receptors and centrally by acting at the hypothalamic–pituitary level. In-vitro and in-vivo studies have shown that glucocorticoids decrease hypothalamic GnRH release and basal- or GnRH-stimulated release of LH, and reduce testis responsiveness to LH and concentrations of LH receptors [57]. Excessive glucocorticoid exposure suppresses androgen synthesis and promotes Leydig cells apoptosis through both genomic and nongenomic actions [58]. Recently, Annie and colleagues showed that dexamethasone affects testicular testosterone production by acting on Leydig cells via the modulation of PGC-1α and visfatin expression, both involved in gonadal steroidogenesis, while concomitantly impairing the differentiation of germ cells [59].
Together with tacrolimus, antimetabolites (in particular, mycophenolic acid) prevent the proliferation of T- and B-lymphocytes and represent the cornerstone of immunosuppressive therapy in KTRs. Although no data have demonstrated that antimetabolites may affect erectile function, some studies have reported that mycophenolic acid may negatively impact reproductive health. Indeed, it alters DNA synthesis through indirect mechanisms [60], leading to mutagenic and teratogenic effects [61]. However, several recent studies have suggested there was no significant increase in the number of congenital anomalies in children born from fathers who were treated with azathioprine or mycophenolate-mofetil [61,62]. There is very limited data on the impact of the more recent belatacept, rituximab, basiliximab, and anti-thymocyte globulin administration on sexual function and male fertility [61].

4. Treatment of ED in Kidney Transplant Recipients

A wide variety of treatments to restore erectile function are safe and effective in KTRs. PDE5 inhibitors (PDE5is) have been studied in these patients, and, among them, sildenafil [63,64,65,66] and vardenafil [67] have been used with success, showing no significant interactions with immunosuppressive drugs [68,69]. Additionally, psychosexual therapy, drug therapy, surgical treatment, transurethral or intracavernosal therapy, vacuum constriction devices, and low-intensity shockwave therapy (LiSWT) may be pursued. The detection of PDE5 expression in the cortex and inner medulla of human kidneys prompted the hypothesis of a possible natriuretic effect other than those exerted on penile vasculature itself. However, sildenafil administration in decompensated cirrhotic patients caused rapid activation of the renin–angiotensin–aldosterone system and sodium retention, which are associated with a decrease in arterial blood pressure [70]. Increased cyclic GMP levels have also been implicated in the control of renin secretion, and the administration of sildenafil exerted a stimulatory effect on renin secretion. This effect may help to explain why sildenafil has a minor effect on blood pressure, despite the widespread distribution of PDE5 in vascular tissues, and it is very safe on KTRs [71]. Sildenafil, the first available oral drug that has proven to be effective and safe for ED treatment in KTRs, as well as in patients undergoing hemodialysis, improves the penetration ability, maintenance frequency, and sexual domain scores (erectile function, sexual desire, intercourse, and overall satisfaction) without influencing the serum concentrations of cyclosporin [72]. Vardenafil is effective and well-tolerated in KTRs and shows similar efficacy and a similar safety profile as sildenafil [73]. The recommended starting dose of sildenafil in patients with severe kidney dysfunction (i.e., CLcr < 30 mL/min) should be 25 mg. Vardenafil 5 mg may be administered in patients with mild, moderate, or severe renal insufficiency [74]. The recommended starting dose of tadalafil, a PDE5i with a long half-life, is 5 mg in patients with moderate kidney insufficiency (CLcr 31–50 mL/minute), and the maximum total dose of 10 mg should not be exceeded in 48 h. For severely impaired patients (CLcr < 30 mL/min) and patients with ESRD undergoing dialysis, a 5-mg total dose in 72 h is recommended. Once-daily treatment is not recommended in patients with CLcr < 30 mL/minute [75] because of poor safety evidence related to KTRs and in patients undergoing dialysis.
As far as hormonal treatment goes, previous studies have found a positive correlation between the hormonal profile of KTRs and sexual function, confirming that the normalization of post-transplantation prolactin and testosterone levels yields several benefits, as well as shifting drug administration, as shown in Table 1 [76]. Interestingly, Chatterjee and colleagues reported that the administration of testosterone replacement therapy and sildenafil in KTRs with hypogonadism promotes an effective response, thereby underlining the importance of evaluating the gonadal function in KTRs with ED [77]. Testosterone exerts a crucial double role in male sexual function; it mediates the sexual desire by acting at the central nervous system level [78] and maintains penile PDE5 expression that triggers the NO cascade, leading to erection [79]. A growing body of evidence has reported that kidney transplantation promotes a significant rescuing of testosterone levels in a subset of KTRs, leading to improvement of ED [80,81]. Conversely, some authors have reported a high prevalence of the HPG axis abnormalities in male KTRs with well-functioning allografts [82]. Indeed, Lofaro and colleagues reported a high prevalence of hypogonadism in male KTRs [13].
Second-line treatments are penile injections and urethral suppositories. Intracavernous injections of alprostadil have been successfully used in immunosuppressed KTRs without any reports of kidney impairment or changes in CNI levels attributable to this treatment for ED [83]. Alprostadil can be usefully delivered by a urethral suppository, and the dosage required is about 25 times higher than that used for intracavernous injection.
Third-line therapy includes penile implants, which should be carefully considered in these patients, taking into account the following aspects: (i) stable graft function for at least 6 months; (ii) low doses of immunosuppressants; (iii) low probability of device malfunction; (iv) no intra-abdominal components to avoid confusion of the reservoir with the bladder in the event of subsequent kidney transplantation; (v) minimum tissue dissection; (vi) no skin or urinary tract infections; (vii) use of prophylactic antibacterials (parenteral, intraurethral, and topical); (viii) treatment with post-operative broad-spectrum oral antibacterials for 1–2 weeks [84].
Low-intensity shockwave therapy (Li-SWT) has recently emerged as a potential treatment for ED, and this has created considerable excitement due to its potential reparative mechanisms promoting the formation of new blood vessels and improving endothelial function in the corpora cavernosa. Yamaçake and colleagues have published promising results of the effects of six treatment sessions, with 7 out of 10 patients in the treatment group experiencing an improvement of at least 5 points in the IIEF-5 score vs. only 1 out of 10 in the sham group [85]. At first glance, this seems to confirm a possible effect of Li-SWT and suggests that the treatment could be offered specifically to KTRs. However, these results must be interpreted cautiously because of the very small number of patients treated.
A pioneering clinical experience evaluated the effectiveness of vacuum therapy in dialysis patients, with 73% achieving erection with the vacuum device. In this study, all hypogonadal men received testosterone therapy via implantation of depo-testosterone [86]. In the future, it will be appropriate to better understand the therapeutic potential of endothelial progenitor cells in these patients [87]. Their significance is certainly more solid from a diagnostic point of view as an early marker of endothelial damage. However, the intracavernous incorporation of these cells, in particular, the immunophenotypic variants with a higher degree of maturation, could represent an interesting challenge.
Although 38% of patients with testosterone deficiency display sexual symptoms, including ED, the latter does not usually correlate with the presence of hypogonadism in male KTRs [17]. Remarkably, it has been reported that in CKD patients, a 22% decrease in the risk of developing cardiovascular events for each nmol-per-liter increment in total testosterone concentration occurs [88]. Karakitsos and colleagues have linked CKD-related hypogonadism to precise clinical measures of endothelial dysfunction, reporting an inverse correlation between serum testosterone levels and intima/media thickness of the carotid artery and left ventricular mass index [89]. Furthermore, testosterone deficiency has been linked to a higher risk of all-cause mortality in male patients with CKD [90], with a more favorable overall prognosis seen in patients with higher testosterone levels undergoing hemodialysis [91]. Although transplantation may revert many of the consequences of renal insufficiency, this is not always the case for hypogonadism, probably because of the concomitant glucocorticoid and immunosuppressant use. Indeed, cyclosporin-A and tacrolimus exert a direct toxic effect on Leydig cells and the hypothalamic–pituitary–gonadal axis. Symptomatic hypogonadism is common in KTRs, as well as during dialysis, and testosterone replacement therapy can be safely prescribed even in the long-term, with significant improvements in anemia [91,92]. Testosterone pellets can be used in immunosuppressed KTRs without infectious complications [93]. Alternatively, the use of human chorionic gonadotropin may help to augment and increase endogenous testosterone levels, as well as the Leydig cell expression of CYP2R1, a key enzyme involved in vitamin D 25-hydroxylation, thus exerting dual protective effects [94].

5. Conclusions

The incidence of ED in patients with ERSD and KTRs is quite high, and its management is particularly difficult due to many interfering factors. The first approach should refer to changing the pharmacological interference scenario, especially for those drugs upsetting sexuality at the central (i.e., gonadotrophins, neurosteroids) and peripheral levels by shifting some adverse treatments to favorable ones whenever possible. The second approach may be to prescribe a PDE5i at a low dosage, considering that if testosterone-circulating levels are compatible with the diagnosis of hypogonadism, its efficacy may only be partial [80]. The possibility of using a combination of testosterone plus PDE5i should be considered, due to the beneficial effects on both systemic and local (penis, kidney) targets. Careful monitoring of KTRs is required both in terms of efficacy and safety because of the possible occurrence of treatment-emergent adverse events requiring drug withdrawal. Finally, topical or intracavernous injections of alprostadil in patients failing first- and second-line treatments are advised in the absence of contraindications. Penile implants should be regarded as third-line options arising from specific patient needs and compliance with the clinical conditions.

Author Contributions

A.A. conceived the idea and revised the manuscript. A.P. wrote the manuscript; G.I. and D.L. performed the literature search and corrected syntax and typos; S.L.V., A.B., and A.E.C. reviewed the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Acknowledgments

The authors wish to thank the Department of Experimental and Clinical Medicine of the University of Catanzaro (Italy) for supporting the publication of the manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kettaş, E.; Çayan, F.; Akbay, E.; Kıykım, A.; Çayan, S. Sexual dysfunction and associated risk factors in women with end-stage renal disease. J. Sex. Med. 2008, 5, 872–877. [Google Scholar] [CrossRef] [PubMed]
  2. Navaneethan, S.D.; Vecchio, M.; Johnson, D.W.; Saglimbene, V.; Graziano, G.; Pellegrini, F.; Lucisano, G.; Craig, J.C.; Ruospo, M.; Gentile, G.; et al. Prevalence and correlates of self-reported sexual dysfunction in CKD: A meta-analysis of observational studies. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 2010, 56, 670–685. [Google Scholar] [CrossRef] [PubMed]
  3. Toorians, A.W.; Janssen, E.; Laan, E.; Gooren, L.J.; Giltay, E.J.; Oe, P.L.; Donker, A.J.; Everaerd, W. Chronic renal failure and sexual functioning: Clinical status versus objectively assessed sexual response. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc. 1997, 12, 2654–2663. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. El-Bahnasawy, M.S.; El-Assmy, A.; El-Sawy, E.; Ali-El Dein, B.; Shehab El-Dein, A.B.; Refaie, A.; El-Hammady, S. Critical evaluation of the factors influencing erectile function after renal transplantation. Int. J. Impot. Res. 2004, 16, 521–526. [Google Scholar] [CrossRef] [PubMed]
  5. Filocamo, M.T.; Zanazzi, M.; Li Marzi, V.; Lombardi, G.; Del Popolo, G.; Mancini, G.; Salvadori, M.; Nicita, G. Sexual dysfunction in women during dialysis and after renal transplantation. J. Sex. Med. 2009, 6, 3125–3131. [Google Scholar] [CrossRef]
  6. Pertuz, W.; Castaneda, D.A.; Rincon, O.; Lozano, E. Sexual dysfunction in patients with chronic renal disease: Does it improve with renal transplantation? Transplant. Proc. 2014, 46, 3021–3026. [Google Scholar] [CrossRef]
  7. Fugl-Meyer, K.S.; Nilsson, M.; Hylander, B.; Lehtihet, M. Sexual Function and Testosterone Level in Men With Conservatively Treated Chronic Kidney Disease. Am. J. Men’s Health 2017, 11, 1069–1076. [Google Scholar] [CrossRef]
  8. Tavallaii, S.A.; Mirzamani, M.; Heshmatzade Behzadi, A.; Assari, S.; Khoddami Vishteh, H.R.; Hajarizadeh, B.; Einollahi, B. Sexual function: A comparison between male renal transplant recipients and hemodialysis patients. J. Sex. Med. 2009, 6, 142–148. [Google Scholar] [CrossRef]
  9. Edey, M.M. Male Sexual Dysfunction and Chronic Kidney Disease. Front. Med. 2017, 4, 32. [Google Scholar] [CrossRef] [Green Version]
  10. Steiner, T.; Wunderlich, H.; Ott, U. Sexuality after kidney transplantation. Urol. A 2009, 48, 1438–1442. [Google Scholar] [CrossRef]
  11. Cummings, J.M.; Boullier, J.A.; Browne, B.J.; Bose, K.; Emovon, O. Male sexual dysfunction in renal transplant recipients: Comparison to men awaiting transplant. Transplant. Proc. 2003, 35, 864–865. [Google Scholar] [CrossRef]
  12. Fiuk, J.V.; Tadros, N.N. Erectile dysfunction in renal failure and transplant patients. Transl. Androl. Urol. 2019, 8, 155–163. [Google Scholar] [CrossRef] [PubMed]
  13. Lofaro, D.; Perri, A.; Aversa, A.; Aquino, B.; Bonofiglio, M.; La Russa, A.; Settino, M.G.; Leone, F.; Ilacqua, A.; Armentano, F.; et al. Testosterone in renal transplant patients: Effect on body composition and clinical parameters. J. Nephrol. 2018, 31, 775–783. [Google Scholar] [CrossRef]
  14. Teng, L.C.; Wang, C.X.; Chen, L. Improved erectile function and sex hormone profiles in male Chinese recipients of kidney transplantation. Clin. Transplant. 2011, 25, 265–269. [Google Scholar] [CrossRef] [PubMed]
  15. Ahmad, M.; Rafiuddin, Q.; Hassan, U.; Ahmad, A.; Husain, S. Impact of renal transplantation on erectile dysfunction due to chronic renal failure in male patients. J. Ayub Med Coll. Abbottabad 2009, 21, 69–71. [Google Scholar]
  16. Mirone, V.; Longo, N.; Fusco, F.; Verze, P.; Creta, M.; Parazzini, F.; Imbimbo, C. Renal transplantation does not improve erectile function in hemodialysed patients. Eur. Urol. 2009, 56, 1047–1053. [Google Scholar] [CrossRef]
  17. Antonucci, M.; Palermo, G.; Recupero, S.M.; Bientinesi, R.; Presicce, F.; Foschi, N.; Bassi, P.; Gulino, G. Male sexual dysfunction in patients with chronic end-stage renal insufficiency and in renal transplant recipients. Arch. Ital. Di Urol. Androl. 2016, 87, 299–305. [Google Scholar] [CrossRef]
  18. De Rosa, S.; Arcidiacono, B.; Chiefari, E.; Brunetti, A.; Indolfi, C.; Foti, D.P. Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and Epigenetic Links. Front. Endocrinol. 2018, 9, 2. [Google Scholar] [CrossRef]
  19. Palella, E.; Cimino, R.; Pullano, S.A.; Fiorillo, A.S.; Gulletta, E.; Brunetti, A.; Foti, D.P.; Greco, M. Laboratory Parameters of Hemostasis, Adhesion Molecules, and Inflammation in Type 2 Diabetes Mellitus: Correlation with Glycemic Control. Int. J. Environ. Res. Public Health 2020, 17, 300. [Google Scholar] [CrossRef] [Green Version]
  20. Tian, Y.; Ji, Z.G.; Tang, Y.W.; Zhang, L.; Lü, W.C.; Lin, J.; Guo, H.B.; Xie, Z.L.; Sun, W.; Du, L.D.; et al. Prevalence and influential factors of erectile dysfunction in male renal transplant recipients: A multiple center survey. Chin. Med J. 2008, 121, 795–799. [Google Scholar] [CrossRef]
  21. Gontero, P.; Oderda, M.; Filippini, C.; Fontana, F.; Lazzarich, E.; Stratta, P.; Turello, E.; Tizzani, A.; Frea, B. Does kidney transplantation onto the external iliac artery affect the haemodynamic parameters of the cavernosal arteries? Asian J. Androl. 2012, 14, 621–625. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Caroleo, M.; Carbone, E.A.; Primerano, A.; Foti, D.; Brunetti, A.; Segura-Garcia, C. The role of hormonal, metabolic and inflammatory biomarkers on sleep and appetite in drug free patients with major depression: A systematic review. J. Affect. Disord. 2019, 250, 249–259. [Google Scholar] [CrossRef] [PubMed]
  23. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg. 2009, 9 (Suppl. 3), S1–S155. [CrossRef] [PubMed]
  24. Naesens, M.; Kuypers, D.R.; Sarwal, M. Calcineurin inhibitor nephrotoxicity. Clin. J. Am. Soc. Nephrol. 2009, 4, 481–508. [Google Scholar] [CrossRef] [Green Version]
  25. Gaston, R.S. Chronic calcineurin inhibitor nephrotoxicity: Reflections on an evolving paradigm. Clin. J. Am. Soc. Nephrol. 2009, 4, 2029–2034. [Google Scholar] [CrossRef] [Green Version]
  26. Opelz, G.; Döhler, B. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009, 87, 795–802. [Google Scholar] [CrossRef]
  27. Rodrigo, E.; Fernández-Fresnedo, G.; Valero, R.; Ruiz, J.C.; Piñera, C.; Palomar, R.; González-Cotorruelo, J.; Gómez-Alamillo, C.; Arias, M. New-onset diabetes after kidney transplantation: Risk factors. J. Am. Soc. Nephrol. 2006, 17, S291–S295. [Google Scholar] [CrossRef] [Green Version]
  28. Hošková, L.; Málek, I.; Kopkan, L.; Kautzner, J. Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension. Physiol. Res. 2017, 66, 167–180. [Google Scholar] [CrossRef]
  29. Mulgaonkar, S.; Kaufman, D.B. Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients. Clin. Transplant. 2014, 28, 1209–1224. [Google Scholar] [CrossRef]
  30. Schena, F.P.; Pascoe, M.D.; Alberu, J.; del Carmen Rial, M.; Oberbauer, R.; Brennan, D.C.; Campistol, J.M.; Racusen, L.; Polinsky, M.S.; Goldberg-Alberts, R.; et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009, 87, 233–242. [Google Scholar] [CrossRef]
  31. Abdel-Hamid, I.A.; Eraky, I.; Fouda, M.A.; Mansour, O.E. Role of penile vascular insufficiency in erectile dysfunction in renal transplant recipients. Int. J. Impot. Res. 2002, 14, 32–37. [Google Scholar] [CrossRef] [Green Version]
  32. Burgos, F.J.; Pascual, J.; Gomez, V.; Orofino, L.; Liaño, F.; Ortuño, J. Effect of kidney transplantation and cyclosporine treatment on male sexual performance and hormonal profile: A prospective study. Transplant. Proc. 1997, 29, 227–228. [Google Scholar] [CrossRef]
  33. Malavaud, B.; Rostaing, L.; Rischmann, P.; Sarramon, J.P.; Durand, D. High prevalence of erectile dysfunction after renal transplantation. Transplantation 2000, 69, 2121–2124. [Google Scholar] [CrossRef] [PubMed]
  34. Park, M.G.; Koo, H.S.; Lee, B. Characteristics of testosterone deficiency syndrome in men with chronic kidney disease and male renal transplant recipients: A cross-sectional study. Transplant. Proc. 2013, 45, 2970–2974. [Google Scholar] [CrossRef] [PubMed]
  35. El-Assmy, A.; El-Bahnasawy, M.S.; Dawood, A.; AboBieh, E.; Ali-El Dein, B.; El-Dein, A.B.; El-Hamady Sel, D. Vasculogenic erectile dysfunction in renal transplant recipients--assessment of potential risk factors. Scand. J. Urol. Nephrol. 2004, 38, 511–516. [Google Scholar] [CrossRef] [PubMed]
  36. Oriji, G.K.; Keiser, H.R. Role of nitric oxide in cyclosporine A-induced hypertension. Hypertension 1998, 32, 849–855. [Google Scholar] [CrossRef] [Green Version]
  37. Lungu, A.O.; Jin, Z.G.; Yamawaki, H.; Tanimoto, T.; Wong, C.; Berk, B.C. Cyclosporin A inhibits flow-mediated activation of endothelial nitric-oxide synthase by altering cholesterol content in caveolae. J. Biol. Chem. 2004, 279, 48794–48800. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Morris, S.T.; McMurray, J.J.; Rodger, R.S.; Farmer, R.; Jardine, A.G. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int. 2000, 57, 1100–1106. [Google Scholar] [CrossRef] [Green Version]
  39. Shihab, F.S.; Yi, H.; Bennett, W.M.; Andoh, T.F. Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int. 2000, 58, 1174–1185. [Google Scholar] [CrossRef] [Green Version]
  40. Esposito, C.; Fornoni, A.; Cornacchia, F.; Bellotti, N.; Fasoli, G.; Foschi, A.; Mazzucchelli, I.; Mazzullo, T.; Semeraro, L.; Dal Canton, A. Cyclosporine induces different responses in human epithelial, endothelial and fibroblast cell cultures. Kidney Int. 2000, 58, 123–130. [Google Scholar] [CrossRef] [Green Version]
  41. Shabsigh, R.; Rajfer, J.; Aversa, A.; Traish, A.M.; Yassin, A.; Kalinchenko, S.Y.; Buvat, J. The evolving role of testosterone in the treatment of erectile dysfunction. Int. J. Clin. Pract. 2006, 60, 1087–1092. [Google Scholar] [CrossRef] [PubMed]
  42. Cavallini, L.; Malendowicz, L.K.; Mazzocchi, G.; Belloni, A.S.; Nussdorfer, G.G. Effects of prolonged cyclosporine-A treatment on the Leydig cells of the rat testis. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 1990, 58, 215–220. [Google Scholar] [CrossRef] [PubMed]
  43. Seethalakshmi, L.; Flores, C.; Malhotra, R.K.; Pallias, J.D.; Tharakan, D.; Khauli, R.B.; Menon, M. The mechanism of cyclosporine’s action in the inhibition of testosterone biosynthesis by rat Leydig cells in vitro. Transplantation 1992, 53, 190–195. [Google Scholar] [CrossRef] [PubMed]
  44. Sikka, S.C.; Coy, D.C.; Lemmi, C.A.; Rajfer, J. Effect of cyclosporine on steroidogenesis in rat Leydig cells. Transplantation 1988, 46, 886–890. [Google Scholar] [CrossRef] [PubMed]
  45. Moreira, B.P.; Oliveira, P.F.; Alves, M.G. Molecular Mechanisms Controlled by mTOR in Male Reproductive System. Int. J. Mol. Sci. 2019, 20. [Google Scholar] [CrossRef] [Green Version]
  46. Bererhi, L.; Flamant, M.; Martinez, F.; Karras, A.; Thervet, E.; Legendre, C. Rapamycin-induced oligospermia. Transplantation 2003, 76, 885–886. [Google Scholar] [CrossRef]
  47. Huyghe, E.; Zairi, A.; Nohra, J.; Kamar, N.; Plante, P.; Rostaing, L. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: An overview. Transpl. Int. Off. J. Eur. Soc. Organ Transplant. 2007, 20, 305–311. [Google Scholar] [CrossRef]
  48. Zuber, J.; Anglicheau, D.; Elie, C.; Bererhi, L.; Timsit, M.O.; Mamzer-Bruneel, M.F.; Ciroldi, M.; Martinez, F.; Snanoudj, R.; Hiesse, C.; et al. Sirolimus may reduce fertility in male renal transplant recipients. Am. J. Transplant. 2008, 8, 1471–1479. [Google Scholar] [CrossRef]
  49. Chen, Y.; Zhang, Z.; Lin, Y.; Lin, H.; Li, M.; Nie, P.; Chen, L.; Qiu, J.; Lu, Y.; Chen, L.; et al. Long-term impact of immunosuppressants at therapeutic doses on male reproductive system in unilateral nephrectomized rats: A comparative study. Biomed Res. Int. 2013, 2013, 690382. [Google Scholar] [CrossRef] [Green Version]
  50. Rovira, J.; Diekmann, F.; Ramírez-Bajo, M.J.; Bañón-Maneus, E.; Moya-Rull, D.; Campistol, J.M. Sirolimus-associated testicular toxicity: Detrimental but reversible. Transplantation 2012, 93, 874–879. [Google Scholar] [CrossRef]
  51. Skrzypek, J.; Krause, W. Azoospermia in a renal transplant recipient during sirolimus (rapamycin) treatment. Andrologia 2007, 39, 198–199. [Google Scholar] [CrossRef] [PubMed]
  52. Dupont, P.; Warrens, A.N. The evolving role of sirolimus in renal transplantation. Qjm 2003, 96, 401–409. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Lee, S.; Coco, M.; Greenstein, S.M.; Schechner, R.S.; Tellis, V.A.; Glicklich, D.G. The effect of sirolimus on sex hormone levels of male renal transplant recipients. Clin. Transplant. 2005, 19, 162–167. [Google Scholar] [CrossRef] [PubMed]
  54. Saunders, R.N.; Metcalfe, M.S.; Nicholson, M.L. Rapamycin in transplantation: A review of the evidence. Kidney Int. 2001, 59, 3–16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Webster, A.C.; Lee, V.W.; Chapman, J.R.; Craig, J.C. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst. Rev. 2006. [Google Scholar] [CrossRef] [PubMed]
  56. Haller, M.C.; Kammer, M.; Kainz, A.; Baer, H.J.; Heinze, G.; Oberbauer, R. Steroid withdrawal after renal transplantation: A retrospective cohort study. BMC Med. 2017, 15, 8. [Google Scholar] [CrossRef] [Green Version]
  57. Calogero, A.E.; Burrello, N.; Bosboom, A.M.; Garofalo, M.R.; Weber, R.F.; D’Agata, R. Glucocorticoids inhibit gonadotropin-releasing hormone by acting directly at the hypothalamic level. J. Endocrinol. Investig. 1999, 22, 666–670. [Google Scholar] [CrossRef]
  58. Hardy, M.P.; Gao, H.B.; Dong, Q.; Ge, R.; Wang, Q.; Chai, W.R.; Feng, X.; Sottas, C. Stress hormone and male reproductive function. Cell Tissue Res. 2005, 322, 147–153. [Google Scholar] [CrossRef]
  59. Annie, L.; Gurusubramanian, G.; Kumar Roy, V. Dexamethasone mediated downregulation of PGC-1α and visfatin regulates testosterone synthesis and antioxidant system in mouse testis. Acta Histochem. 2019, 121, 182–188. [Google Scholar] [CrossRef]
  60. Midtvedt, K.; Bergan, S.; Reisæter, A.V.; Vikse, B.E.; Åsberg, A. Exposure to Mycophenolate and Fatherhood. Transplantation 2017, 101, e214–e217. [Google Scholar] [CrossRef] [Green Version]
  61. Semet, M.; Paci, M.; Saïas-Magnan, J.; Metzler-Guillemain, C.; Boissier, R.; Lejeune, H.; Perrin, J. The impact of drugs on male fertility: A review. Andrology 2017, 5, 640–663. [Google Scholar] [CrossRef] [PubMed]
  62. Lopez-Lopez, I.; Rodelo-Haad, C.; Agüera, M.L.; Cabello-Jabalquinto, R.; Esquivias-Motta, E.; Navarro, M.D.; Aljama, P.; Rodriguez-Benot, A. Administration of mycophenolic acid is not associated with malformations in descendants from kidney transplanted males. PLoS ONE 2018, 13, e0202589. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Barrou, B.; Cuzin, B.; Malavaud, B.; Petit, J.; Pariente, J.L.; Buchler, M.; Cormier, L.; Benoit, G.; Costa, P. Early experience with sildenafil for the treatment of erectile dysfunction in renal transplant recipients. Nephrol. Dial. Transplant. 2003, 18, 411–417. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Prieto Castro, R.M.; Anglada Curado, F.J.; Regueiro López, J.C.; Leva Vallejo, M.E.; Molina Sánchez, J.; Saceda López, J.L.; Requena Tapia, M.J. Treatment with sildenafil citrate in renal transplant patients with erectile dysfunction. BJU Int. 2001, 88, 241–243. [Google Scholar] [CrossRef] [PubMed]
  65. Russo, D.; Musone, D.; Alteri, V.; Cindolo, L.; Lanzillo, B.; Federico, S.; Andreucci, V.E. Erectile dysfunction in kidney transplanted patients: Efficacy of sildenafil. J. Nephrol. 2004, 17, 291–295. [Google Scholar]
  66. Sharma, R.K.; Prasad, N.; Gupta, A.; Kapoor, R. Treatment of erectile dysfunction with sildenafil citrate in renal allograft recipients: A randomized, double-blind, placebo-controlled, crossover trial. Am. J. Kidney Dis. 2006, 48, 128–133. [Google Scholar] [CrossRef] [PubMed]
  67. Demir, E.; Balal, M.; Paydas, S.; Sertdemir, Y.; Erken, U. Efficacy and safety of vardenafil in renal transplant recipients with erectile dysfunction. Transplant. Proc. 2006, 38, 1379–1381. [Google Scholar] [CrossRef]
  68. Cofán, F.; Gutiérrez, R.; Beardo, P.; Campistol, J.M.; Oppenheimer, F.; Alcover, J. Interaction between sildenafil and calcineurin inhibitors in renal transplant recipients with erectile dysfunction. Nefrologia 2002, 22, 470–476. [Google Scholar]
  69. Zhang, W.D.; Fan, J.M.; Guan, J.; Peng, G.H.; Zhou, L.; Jian, X.; Chen, M.; Liu, X.H.; Zhang, P.S. Studies on sexual dysfunction in male patients with chronic renal insufficiency. Natl. J. Androl. 2003, 9, 489–493. [Google Scholar]
  70. Thiesson, H.C.; Jensen, B.L.; Jespersen, B.; Schaffalitzky de Muckadell, O.B.; Bistrup, C.; Walter, S.; Ottosen, P.D.; Veje, A.; Skøtt, O. Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am. J. Physiol. Ren. Physiol. 2005, 288, F1044–F1052. [Google Scholar] [CrossRef]
  71. Chiu, Y.J.; Reid, I.A. Effect of sildenafil on renin secretion in human subjects. Exp. Biol. Med. 2002, 227, 620–625. [Google Scholar] [CrossRef]
  72. Liu, L.Y.; Sun, T.; Liu, Y.; Sun, Y.Y.; Ma, F.Z. The Clinical Effects of Sildenafil for Erection in Patients after Kidney Transplantation: A Meta-Analysis. Nephron 2019, 141, 1–9. [Google Scholar] [CrossRef] [PubMed]
  73. Lasaponara, F.; Sedigh, O.; Pasquale, G.; Bosio, A.; Rolle, L.; Ceruti, C.; Timpano, M.; Negro, C.L.; Paradiso, M.; Abbona, A.; et al. Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients with end-stage renal disease receiving dialysis or after renal transplantation. J. Sex. Med. 2013, 10, 2798–2814. [Google Scholar] [CrossRef] [PubMed]
  74. LEVITRA® (vardenafil). Full Prescribing Information; Bayer Pharmaceuticals Corporation: West Haven, CT, USA, 2008. [Google Scholar]
  75. CIALIS® (tadalafil). Full Prescribing Information; Lilly ICOS LLC: Indianapolis, IN, USA, 2009. [Google Scholar]
  76. Barroso, L.V.; Miranda, E.P.; Cruz, N.I.; Medeiros, M.A.; Araújo, A.C.; Mota Filho, F.H.; Medeiros, F.C. Analysis of sexual function in kidney transplanted men. Transplant. Proc. 2008, 40, 3489–3491. [Google Scholar] [CrossRef] [PubMed]
  77. Chatterjee, R.; Wood, S.; McGarrigle, H.H.; Lees, W.R.; Ralph, D.J.; Neild, G.H. A novel therapy with testosterone and sildenafil for erectile dysfunction in patients on renal dialysis or after renal transplantation. J. Fam. Plan. Reprod. Health Care 2004, 30, 88–90. [Google Scholar] [CrossRef] [Green Version]
  78. Saad, F.; Grahl, A.S.; Aversa, A.; Yassin, A.A.; Kadioglu, A.; Moncada, I.; Eardley, I. Effects of testosterone on erectile function: Implications for the therapy of erectile dysfunction. BJU Int. 2007, 99, 988–992. [Google Scholar] [CrossRef]
  79. Aversa, A.; Duca, Y.; Condorelli, R.A.; Calogero, A.E.; La Vignera, S. Androgen Deficiency and Phosphodiesterase Type 5 Expression Changes in Aging Male: Therapeutic Implications. Front. Endocrinol. 2019, 10, 225. [Google Scholar] [CrossRef] [Green Version]
  80. Akbari, F.; Alavi, M.; Esteghamati, A.; Mehrsai, A.; Djaladat, H.; Zohrevand, R.; Pourmand, G. Effect of renal transplantation on sperm quality and sex hormone levels. BJU Int. 2003, 92, 281–283. [Google Scholar] [CrossRef]
  81. Reinhardt, W.; Kübber, H.; Dolff, S.; Benson, S.; Führer, D.; Tan, S. Rapid recovery of hypogonadism in male patients with end stage renal disease after renal transplantation. Endocrine 2018, 60, 159–166. [Google Scholar] [CrossRef]
  82. Tauchmanovà, L.; Carrano, R.; Sabbatini, M.; De Rosa, M.; Orio, F.; Palomba, S.; Cascella, T.; Lombardi, G.; Federico, S.; Colao, A. Hypothalamic-pituitary-gonadal axis function after successful kidney transplantation in men and women. Hum. Reprod. 2004, 19, 867–873. [Google Scholar] [CrossRef] [Green Version]
  83. Mansi, M.K.; Alkhudair, W.K.; Huraib, S. Treatment of erectile dysfunction after kidney transplantation with intracavernosal self-injection of prostaglandin E1. J. Urol. 1998, 159, 1927–1930. [Google Scholar] [CrossRef]
  84. Barry, J.M. Treating erectile dysfunction in renal transplant recipients. Drugs 2007, 67, 975–983. [Google Scholar] [CrossRef] [PubMed]
  85. Yamaçake, K.G.R.; Carneiro, F.; Cury, J.; Lourenço, R.; Françolin, P.C.; Piovesan, A.C.; Srougi, M.; Nahas, W.C.; Antonopoulos, I.M. Low-intensity shockwave therapy for erectile dysfunction in kidney transplant recipients. A prospective, randomized, double blinded, sham-controlled study with evaluation by penile Doppler ultrasonography. Int. J. Impot. Res. 2019, 31, 195–203. [Google Scholar] [CrossRef]
  86. Lawrence, I.G.; Price, D.E.; Howlett, T.A.; Harris, K.P.; Feehally, J.; Walls, J. Correcting impotence in the male dialysis patient: Experience with testosterone replacement and vacuum tumescence therapy. Am. J. Kidney Dis. 1998, 31, 313–319. [Google Scholar] [CrossRef]
  87. Condorelli, R.A.; Calogero, A.E.; Vicari, E.; Favilla, V.; Morgia, G.; Cimino, S.; La Vignera, S. Vascular regenerative therapies for the treatment of erectile dysfunction: Current approaches. Andrology 2013, 1, 533–540. [Google Scholar] [CrossRef]
  88. Yilmaz, M.I.; Sonmez, A.; Qureshi, A.R.; Saglam, M.; Stenvinkel, P.; Yaman, H.; Eyileten, T.; Caglar, K.; Oguz, Y.; Taslipinar, A.; et al. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2011, 6, 1617–1625. [Google Scholar] [CrossRef]
  89. Karakitsos, D.; Patrianakos, A.P.; De Groot, E.; Boletis, J.; Karabinis, A.; Kyriazis, J.; Samonis, G.; Parthenakis, F.I.; Vardas, P.E.; Daphnis, E. Androgen deficiency and endothelial dysfunction in men with end-stage kidney disease receiving maintenance hemodialysis. Am. J. Nephrol. 2006, 26, 536–543. [Google Scholar] [CrossRef]
  90. Haring, R.; Nauck, M.; Völzke, H.; Endlich, K.; Lendeckel, U.; Friedrich, N.; Dörr, M.; Rettig, R.; Kroemer, H.K.; Wallaschofski, H. Low serum testosterone is associated with increased mortality in men with stage 3 or greater nephropathy. Am. J. Nephrol. 2011, 33, 209–217. [Google Scholar] [CrossRef]
  91. Majdan, M.; Kotarski, J.; Ksiaźek, A.; Grzebalska, A. Relationship between some prognostic markers of HD patients and serum erythropoietin, insulin-like growth factor-1, leptin, parathormone and testosterone. Int. Urol. Nephrol. 1999, 31, 563–569. [Google Scholar] [CrossRef]
  92. Brockenbrough, A.T.; Dittrich, M.O.; Page, S.T.; Smith, T.; Stivelman, J.C.; Bremner, W.J. Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. Am. J. Kidney Dis. 2006, 47, 251–262. [Google Scholar] [CrossRef]
  93. Majzoub, A.; Shoskes, D.A. A case series of the safety and efficacy of testosterone replacement therapy in renal failure and kidney transplant patients. Transl. Androl. Urol. 2016, 5, 814–818. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. De Toni, L.; De Filippis, V.; Tescari, S.; Ferigo, M.; Ferlin, A.; Scattolini, V.; Avogaro, A.; Vettor, R.; Foresta, C. Uncarboxylated osteocalcin stimulates 25-hydroxy vitamin D production in Leydig cell line through a GPRC6a-dependent pathway. Endocrinology 2014, 155, 4266–4274. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Table
Table 1. Factors and conditions influencing erectile dysfunction (ED) in chronic kidney disease (CKD)/kidney transplantation recipients (KTRs).
Table 1. Factors and conditions influencing erectile dysfunction (ED) in chronic kidney disease (CKD)/kidney transplantation recipients (KTRs).
Factor/ConditionEvidence
Hormonal abnormalitiesHypergonadotropic hypogonadism: ↓ Total and free T
= SHBG activity/levels
↑LH, ↑FSH
Leydig/Sertoli cells function impairment
Hypogonadotropic hypogonadism:
↑PRL→ ↓GnRH→ ↓LH → ↓T
T deficit:
↓ sexual desire/erectile function
corporal veno-occlusive dysfunction and fibrosis
altered nitrergic activity and PDE5 expression
↑17ß-estradiol
Cardiovascular and endothelial dysfunctionDirect impact:
↓Endothelial function→↓NO→ED
Indirect impact:
MS→ CVD→ ED
HypercholesterolemiaEndothelial dysfunction→ ↓NO→ ↓ L-arginine synthesis/availability →vasculogenic ED
Negative impact on penile hemodynamics
Nervous system abnormalitiesAutonomic neuropathy secondary to DM or CKD Peripheral neuropathy secondary to DM or CKD
Polyneuropathy
Vitamin D deficiency/hyperparathyroidism↓1,25 (OH) Vitamin D→↑ PTH
↑ PTH→↑ PRL→ ↑ED
Zinc depletionDirect zinc removal during hemodialysis/↓GI zinc absorption→↓T→ED
EPO resistant anemia
Altered hematopoietic progenitor cell development Sometimes no reversal ED after zinc supplementation
Anemia↓ EPO→ normocytic normochromic anemia
↓EPO→ ↓T, ↑PRL
↓EPO→ ↓ neuroprotective, antiapoptotic and angiogenic effects of EPO
Anemia→ hypoxia→ ↓NO synthase activity, ↑ increased collagen synthesis→ ↓ relaxation of corpus cavernosum smooth muscle cells→ ED
AgeDirect correlation with prevalence and gravity of ED
EducationInverse correlation with ED
Voluptuous habitsRole still unclear
Detrimental effect of smoking on erectile function
No correlation between smoking and ED in KTR in some studies
Duration time of dialytic treatmentDirect correlation with penile morphological and hemodynamic abnormalities
Greater improvement of ED in KTR underwent to dialysis for 6 months
No improvement of ED in KTR underwent to dialysis for 6–24 months
Effect of early transplantation in the prevention/reverse of penile vasculopathy or sex hormones abnormalities
DrugsAntihypertensive, thiazides, aldosterone receptor blockers, and beta-adrenergic receptor blockers, cimetidine, tricyclic antidepressants, metoclopramide→ onset/exacerbation of ED
Calcineurin inhibitors (cyclosporin A, tacrolimus) → maintenance of the endothelial and gonadic dysfunction previously determined by uremiam
TOR inhibitors/corticosteroids→ impact on testicular function and/or structure
>1 antihypertensive drug administration→ ↑ prevalence of ED
Association between ACEI/ARBs and DE
Surgical proceduresInterruption of arteria iliac distal end→ blood flow→ ED
ED in end-to-end anastomosis to the internal iliac artery > ED end-to-side anastomosis to the external iliac artery
Slight ↓in penile arterial inflow in KTR onto external iliac artery→ ED
Iterative transplantation→ end-to-side anastomosis on internal iliac artery→ penile hypoafflux→ ED
Psychosocial factorsDepression, anxiety, worrying, ↓health-related quality of life→ ED
Altered body’s image perception→ ED and sexual function
Somatic, relational and psychosocial comorbidities
ED: erectile dysfunction; KTR: kidney transplantation recipient; ↑: increased; ↓: decreased; =: unchanged; T: testosterone; SHBG: Sex Hormone Binding Globulin; LH: luteinizing hormone; FSH: follicle-stimulant hormone; GnRH: gonadotropin-releasing hormone; PRL: prolactin; PDE5: phosphodiesterase-5; NO: nitric oxide; MS: metabolic syndrome; CVD: cardiovascular disease; DM: diabetes mellitus; CKD: chronic kidney disease; PTH: parathyroid hormone; EPO: erythropoietin; ACEI: angiotensin-converting-enzyme (ACE) inhibitors; ARBs: angiotensin II receptor blockers.

Share and Cite

MDPI and ACS Style

Perri, A.; Izzo, G.; Lofaro, D.; La Vignera, S.; Brunetti, A.; Calogero, A.E.; Aversa, A. Erectile Dysfunction after Kidney Transplantation. J. Clin. Med. 2020, 9, 1991. https://doi.org/10.3390/jcm9061991

AMA Style

Perri A, Izzo G, Lofaro D, La Vignera S, Brunetti A, Calogero AE, Aversa A. Erectile Dysfunction after Kidney Transplantation. Journal of Clinical Medicine. 2020; 9(6):1991. https://doi.org/10.3390/jcm9061991

Chicago/Turabian Style

Perri, Anna, Giulia Izzo, Danilo Lofaro, Sandro La Vignera, Antonio Brunetti, Aldo Eugenio Calogero, and Antonio Aversa. 2020. "Erectile Dysfunction after Kidney Transplantation" Journal of Clinical Medicine 9, no. 6: 1991. https://doi.org/10.3390/jcm9061991

APA Style

Perri, A., Izzo, G., Lofaro, D., La Vignera, S., Brunetti, A., Calogero, A. E., & Aversa, A. (2020). Erectile Dysfunction after Kidney Transplantation. Journal of Clinical Medicine, 9(6), 1991. https://doi.org/10.3390/jcm9061991

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop